CELC — Celcuity Inc. stock price, charts and financials

Latest market price

80.61

-4.30-5.06%

Overview Short InterestFilings

CELCQT59Celcuity Inc.·NASDAQ

Overview Short InterestFilings

80.61-5.06%

News

Down 5.1% — Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion (SeekingAlpha).

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ABCL-0.79%$12.63 CPRX+0.00%$31.49 XENE-30.69%$39.75 RLAY-1.82%$18.84 PRTC+1.99%$17.42 IDYA-0.52%$38.41 AMLX-4.51%$32.41 TLX+0.64%$12.59

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	24.63%	Shs Outstand	48.77M	Perf Week	-3.40%

Market Cap	3.93B	Forward P/E	-	EPS next Y	-1.47	Insider Trans	-26.12%	Shs Float	29.91M	Perf Month	-13.92%

Enterprise Value	4.50B	PEG	0.90	EPS next Q	-1.50	Inst Own	-	Short Float	35.73%	Perf Quarter	-8.15%

Income	-201.66M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	7.23	Perf Half Y	-28.66%

Sales	0.00	P/B	-	EPS next Y	69.66%	ROA	-27.35%	Short Interest	10.69M	Perf YTD	-19.18%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-350.78%	52W High	151.01 -46.62%	Perf Year	47.64%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-28.14%	52W Low	44.42 81.47%	Perf 3Y	750.32%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	3.94% 4.04%	Perf 5Y	280.59%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-51.94%	Oper. Margin	0.00%	ATR (14)	4.21	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	8.93	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	36.22	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	8.93	EPS Q/Q	-38.46%	SMA20	-9.89%	Beta	0.11	Target Price	159.88

Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	-10.85%	Rel Volume	1.18	Prev Close	84.91

Employees	155	LT Debt/Eq	1.93	Earnings	Nov 11	SMA200	-23.67%	Avg Volume	1.20M	Price	80.61

IPO Date	Sep 19, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.65% -	Net Debt/EBITDA	-3.09	Volume	1,405,857	Change	-5.06%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-17-26	Reiterated	Guggenheim	Buy	$165 → $175
Aug-14-26	Reiterated	Needham	Buy	$157 → $140
Jul-15-26	Reiterated	Craig-Hallum	Buy	$171 → $178
Jul-15-26	Reiterated	HC Wainwright & Co.	Buy	$145 → $155
Jun-03-26	Reiterated	HC Wainwright & Co.	Buy	$185 → $145
Jun-03-26	Reiterated	Craig-Hallum	Buy	$189 → $171
Jun-03-26	Reiterated	Wells Fargo	Overweight	$183 → $166
Jun-02-26	Reiterated	Leerink Partners	Outperform	$155
May-28-26	Reiterated	Macquarie		$160
May-18-26	Reiterated	HC Wainwright & Co.	Buy	$165 → $185

Latest News· Times ET

Sep-18-26

Sep-18-2601:20AM

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug ExpansionSeekingAlpha

Sep-11-26

Sep-11-2609:35AM

10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga

Sep-09-26

Sep-09-2608:57AM

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcriptseekingalpha.com

Sep-01-26

Sep-01-2604:30AM

Celcuity To Participate in Upcoming Investor Conferencesglobenewswire.com

Aug-26-26

Aug-26-2604:31AM

Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast CancerBenzinga

04:30AM

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancerglobenewswire.com

Aug-24-26

Aug-24-2611:55PM

Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELCdefenseworld.net

Aug-17-26

Aug-17-2605:16AM

Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175Benzinga

Aug-14-26

Aug-14-2605:11AM

Celcuity: REVTORPYK Is Now A Commercial Storyseekingalpha.com

04:29AM

Celcuity Analysts Slash Their Forecasts After Q2 Lossbenzinga.com

Aug-13-26

Aug-13-2607:57PM

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcriptseekingalpha.com

03:04PM

Celcuity Q2 Earnings Call Highlightsmarketbeat.com

01:24PM

Celcuity Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga

12:06PM

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com

Aug-10-26

Aug-10-2612:51AM

California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELCdefenseworld.net

Company

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	27	9	6	—	—	—	—	—	—
Research and Development	145	104	61	—	—	—	—	—	—
Other Operating Expense	0	0	-1	—	—	—	—	—	—
Operating Income	-172	-113	-66	—	—	—	—	—	—
Interest Expense	17	10	5	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	12	8	—	—	—	—	—	—
Net Income Before Taxes	-177	-112	-64	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-177	-112	-64	—	—	—	—	—	—
Net Income From Continuing Operations	-177	-112	-64	—	—	—	—	—	—
Net Income	-177	-112	-64	—	—	—	—	—	—
EPS (Recurring)	-3.78	-2.83	-2.69	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.78	-2.83	-2.69	—	—	—	—	—	—
EPS (Diluted)	-3.78	-2.83	-2.69	—	—	—	—	—	—
EBITDA	-160	-101	-58	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	53	39	24	—	—	—	—	—	—
Market Capitalization	5,286	511	350	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	other: Former 10% owner	Jul 14 '26	Sale	102.50	3,100,000	317,750,000	442,940	Jul 16
Laing Lance G.	Chief Science Officer	Jun 02 '26	Option Exercise	9.89	1,000	9,890	1,251,000	Jun 04
Dalvey David	Director	May 04 '26	Sale	140.68	25,000	3,517,000	65,000	May 06
Buller Richard E	Director	May 04 '26	Option Exercise	5.10	9,000	45,900	15,760	May 06
Buller Richard E	Director	May 04 '26	Sale	140.46	9,000	1,264,181	6,760	May 06
Buller Richard E	Director	Mar 31 '26	Option Exercise	5.10	3,000	15,300	9,760	Apr 02
Buller Richard E	Director	Mar 31 '26	Sale	110.27	3,000	330,804	6,760	Apr 02
Dalvey David	Director	Jan 27 '26	Sale	120.03	20,000	2,400,538	90,000	Jan 29
Buller Richard E	Director	Dec 05 '25	Sale	105.69	3,000	317,069	6,760	Dec 09
Buller Richard E	Director	Dec 05 '25	Option Exercise	5.50	3,000	16,500	9,760	Dec 09
Furcht Leo	Director	Dec 04 '25	Option Exercise	7.60	250	1,900	11,000	Dec 08
Buller Richard E	Director	Dec 01 '25	Option Exercise	14.83	1,100	16,313	8,360	Dec 03
Buller Richard E	Director	Dec 01 '25	Sale	98.13	1,100	107,948	7,260	Dec 03
Dalvey David	Director	Nov 21 '25	Sale	100.00	15,000	1,500,017	110,000	Nov 24
Buller Richard E	Director	Nov 20 '25	Option Exercise	14.83	3,900	57,837	11,160	Nov 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.